secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2026-10-15T20:02:19+00:00
Accession:  0001628280-26-065992
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.07
LLM model:  deepseek-v4.1-flash:cloud@v2

Senti Bio holders approve ST NewCo merger and 1-for-20 to 1-for-50 reverse split
--------------------------------------------------------------------------------

- Merger Agreement with ST NewCo Limited, Senti Merger Sub, Midco and Senti Biosciences approved 15,851,146 to 4,325,620; majority-of-the-minority vote 6,074,146 for.
- Stockholders authorized a reverse stock split at a ratio of any whole number from 1-for-20 to 1-for-50, with the Board setting the ratio and power to abandon it.
- Approved under Nasdaq Rule 5635(d) the issuance of more than 19.99% of outstanding shares upon exchange of Midco's Senior Secured Convertible Notes.
- Class I directors Timothy Lu, Edward Mathers and Frances D. Schulz elected to serve until 2029; Mathers drew 4,287,567 withheld votes.
- KPMG LLP ratified as auditor for FY2026 (20,133,068 for); 20,240,055 of 31,145,390 shares (64.98%) represented at the reconvened October 15, 2026 meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000162828026065992/0001628280-26-065992-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000162828026065992/snti-20261015.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-065992

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer